Summary The effect of low (0.08,uUg-' body wtmin-1) and high (0.16YuUg-' body wtmin-') rates of vasopressin infusion on blood flow to normal liver tissue and to liver metastases derived from azoxymethane induced colorectal carcinomas was studied in 36 male Wistar rats. 
vasopressin infusion on blood flow to normal liver tissue and to liver metastases derived from azoxymethane induced colorectal carcinomas was studied in 36 male Wistar rats. Portal venous flow was measured by electromagnetic flowmetry and blood flow to normal and metastatic liver tissue by the clearance of xenon-133 injected directly into the liver parenchyma or metastasis. The low rate of vasopressin infusion decreased portal venous flow but increased blood flow to normal and metastatic liver tissue while at the higher rate of infusion these effects were reversed. Hepatic artery ligation (HAL) immediately following a low rate of vasopressin infusion abolished the observed increase in blood flow to both normal liver tissue and metastases. HAL immediately following the higher rate of vasopressin infusion further reduced blood flow to metastases but did not further alter blood flow to normal liver tissue. HAL prior to the infusion of the vasoactive drug significantly reduced blood flow to metastatic liver tissue, increased portal venous flow and was without effect on blood flow to normal liver tissue. Following HAL, blood flow to metastatic liver tissue was not further altered by either the low or high rates of vasopressin infusion. However, blood flow to normal liver tissue after HAL was reduced by a low rate of infusion of vasopressin and increased by the higher rate of infusion. The results of this study indicate that blood flow to normal or metastatic liver tissue can be increased or decreased by differential rates of infusion of vasopressin. These observations may have important implications in the treatment of liver metastases in man where different rates of vasopressin infusion may potentiate the effects of hepatic artery ligation or cytotoxic therapy.
Hepatic metastases are present in approximately 20% of patients with colorectal carcinoma at initial presentation (Bengmark & Hafstrom, 1969; Oxley & Ellis, 1969; Neilson et al., 1973) . The prognosis of these patients is poor, the median survival being reported to be from 3-9 months (Oxley & Ellis, 1969; Nelson et al., 1973) . There is therefore, a great need for more satisfactory management to improve outlook and prolong survival.
Metastases in the liver obtain the majority, if not all their blood supply from the hepatic artery (Breedis & Young, 1954; Ackerman et al., 1969) . Therefore hepatic metastases have been treated by delivery of a chemotherapeutic agent via the hepatic artery (Mattson et al., 1980; Reed et al., 1980) . Although several reports have suggested a higher rate of palliation with the intra-arterial infusion of chemotherapeutic agents compared to systemic chemotherapy, a recent prospective study has failed to substantiate these claims (Grage et al., 1979) . The dependence of liver metastases on the hepatic artery has also led to attempts to treat nonresectable cases either by ligation or embolisation, followed by chemotherapy (Namamura et al., 1981) . However, these procedures have proved to be disappointing in improving long-term symptomfree survival.
Vasopressin has been used for several years for the initial treatment of bleeding oesophageal varices (Kehne et al., 1956; Shields, 1977 (Chojkier et al., 1979; Mooney et al., 1980 Vasopressin was administered at two rates of infusion, 0.08 and 0.16jUg-1 body wtmin-1 to two groups of 6 rats. These rates of vasopressin infusion were selected on the basis of previous observations in the "normal" rat (Mooney et al., 1980) . The hormone was infused via a cannula placed in the femoral vein for 20 min, the total volume of infusate being 0.2 ml. A control group of 6 azoxymethane treated rats received a 20 min infusion of the same volume of isotonic saline.
Arterial (Lewis, 1970; Gelin et al., 1968; Taylor et al., 1979) . A small volume (2,l) of 133Xe was injected into the liver substance or a hepatic metastasis using a fine needle, which was held in place for several seconds to prevent leakage along the needle track. The clearance of 133Xe from the liver was measured by external scanning using a collimated sodium-iodide scintillation counter attached to a pen recorder. Since in the rat, the clearance of 133Xe following parenchymal injection follows a monoexponential curve, liver blood flow was calculated from the formula K100, where K is the exponential rate constant (and is equal to 0.693/t2, where t-is the time taken for hepatic activity to fall to half its initial value) and A is the partition coefficient of liver tissue (McKenzie et al., 1976; Conn, 1961) .
Liver blood flow to metastatic tissue was calculated using the same formula as that used for normal tissue, the partition coefficient for metastatic tissue being the same as normal liver tissue (Mooney, 1981) .
Liver blood to flow to normal and metastatic tissue was measured before and after the infusion of vasopressin. Immediately following the infusion of vasopressin the hepatic artery was ligated and the haemodynamic measurements were repeated.
Study 2: The effect of vasopressin on hepatic haemodynamics following hepatic artery ligation
The experimental set-up was essentially the same as in the first study, except that the hepatic artery was ligated after basal measurements of portal venous flow, liver blood flow and arterial blood pressure.
The haemodynamic measurements were repeated immediately after and 10min following hepatic artery ligation. Vasopressin was then infused at either 0.08 or 0.l6piUg-1 body wtmin-1 to two groups of 6 rats for 20 min, the total volume of infusate being 0.2 ml. A control group of azoxymethane treated rats received a similar infusion of isotonic saline. Arterial pressure and portal venous flow were again recorded continuously throughout the experiment and measurements of blood flow to normal and metastatic tissue repeated at the end of the infusion.
Statistical analysis
The statistical significance of any differences in hepatic haemodynamics were evaluated using Student's t-test for paired and unpaired data.
Results

Histology
The livers of all animals treated with azoxymethane showed some evidence of liver damage, notably hepatocyte swelling and some necrosis. However, cirrhosis was not present nor were there any foci of microcancer. The results are expressed as Mean + s.e. aDenotes a significant difference from the balsal levels (P <0.05). Furthermore, liver blood flow measured by the clearance of xenon-133 is lower in azoxymethane treated rats than in untreated rats (Mooney & Taylor, 1981) . However, hepatic artery ligation has no effect on blood flow to the liver of azoxymethane treated rats (Mooney & Taylor, 1981) . Therefore, in this study non-metastatic tissue is referred to as "normal", although we accept that there is some hepatocellular damage and impairment of blood flow. The results of this study clearly indicate that the effects of vasopressin on portal venous flow and blood flow to normal and metastatic tissue are dependent on the rate of its infusion. The response is biphasic, and accords with previous observations (Mooney et al., 1980) . Thus at the lower rate of vasopressin infusion (0.08 ,U g-' body wt min-1) portal venous flow was decreased but total blood flow to normal and metastatic liver tissue was increased; at a higher rate of infusion (0.16pUg'1 body wtmin-1) these effects were reversed. These contrasting responses were consistently observed (Figure 1 ).
The precise mechanism whereby vasopressin brings about the observed changes in portal venous flow is not clear. The most generally accepted explanation is that the fall in portal venous flow following vasopressin infusion is the result of constriction of the splanchnic arterioles (Schwartz, 1970) , although a direct effect on the intraheptic portal resistance sites has also been suggested (Richardson & Withrington, 1981 The precise mechanism whereby vasopressin elicits an increased flow in the hepatic artery is not clear. Conn (1973) has suggested that the increase in hepatic artery flow following vasopressin infusion is secondary to a reduction in portal flow. However, the hepatic artery-response to vasopressin is much greater when the hormone is administered intraarterially than intravenously suggesting a direct effect on the artery (Richardson & Withrington, 1975) . Nevertheless, the "dilator" effect of vasopressin on the hepatic arterial bed may be indirect and reflect passive dilation of the prearteriolar vessels due to increases in systemic blood pressure (Richardson & Withrington, 1981) . The reduction in blood flow to normal and metastatic liver tissue following a higher rate of vasopressin infusion (0.16 yU g1 body wt min-') would again seem to reflect an alteration in hepatic artery flow, since portal venous flow at this rate of infusion was increased. This suggestion is supported by the observation that hepatic artery ligation significantly reduced blood flow to metastatic tissue whose blood supply is derived predominantly from the hepatic artery. Conversely hepatic artery ligation had little effect on blood flow to "normal" liver tissue which receives a blood supply from both the hepatic artery and portal vein, portal venous flow being increased following an infusion of 0.16,1Ug-' body wtmin-m vasopressin. Furthermore, ligation of the hepatic artery prior to the infusion of 0.16 pU g`body wt min-vasopressin, abolished the reduction in blood supply to liver metastases when the hormone was infused at this higher rate without prior ligation. Vasopressin has been reported to elicit hepatic artery vasoconstriction in the dog (Richardson & Withrington, 1975) . Possibly, therefore, at a rate of infusion of 0.16 ,uU g1 body wt min-1 the hepatic artery cannot escape the generalised vasoconstrictor properties of the hormone, and this results in a decreased flow through the hepatic artery and an overall decrease in liver blood flow.
The observations of this study on the effects of different rates of infusion of vasopressin on hepatic haemodynamics may have important practical implications in the management of patients presenting with liver metastases. Firstly, vasopressin infusion at a rate comparable to that currently used for the management of bleeding oesophageal varices, may, by reducing portal venous flow, potentiate the effects of hepatic artery ligation or embolisation in rendering tumour tissue ischaemic. Secondly, since this rate of vasopressin infusion increases hepatic artery flow, the simultaneous administration of vasopressin and a cytotoxic agent may ensure a preferential delivery of the latter to liver metastases. Lastly, a higher rate of infusion of vasopressin that is currently used for the emergency control of bleeding oesophageal varices, by increasing portal venous flow, may potentiate cytotoxic therapy given via the portal vein in combination with hepatic artery ligation or embolisation.
